...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >S-1, Oxaliplatin, Nab-paclitaxel and Itraconazole for Conversion Surgery for Advanced or Recurrent Gastric Cancer
【24h】

S-1, Oxaliplatin, Nab-paclitaxel and Itraconazole for Conversion Surgery for Advanced or Recurrent Gastric Cancer

机译：S-1，Oxaliplatin，Nab-κBlitaxel和Itraconazole用于转化手术，用于晚期或复发性胃癌

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: To evaluate the efficacy of chemotherapy with itraconazole for advanced or recurrent gastric cancer. Patients and Methods: Patients with human epidermal growth factor receptor 2 (HER2) negative unresectable gastric cancer referred to our hospital were included. The regimen comprised 160 mg/m(2) nab-paclitaxel i.v. and 100 mg/m2 oxaliplatin i.v. on day 1, 60 mg/m2 S-1 orally on days 1-3, and 400 mg itraconazole orally on days -2 to 2, repeated every 2 weeks for 6-8 cycles. Results: Twenty-three patients aged 40-80 years (median age=68 years) were enrolled, of whom 21 had stomach cancer and two gastroesophageal junction cancer. Regarding stage, two, one, and 20 patients had stage IIIA, IIIB, and IV, respectively. Among patients with liver metastases, 2/10 had simultaneous lung metastases. Nine patients had peritoneal dissemination, and five patients with stage IV disease developed recurrence after primary surgery followed by adjuvant S-1. The other 18 patients had no history of surgery or chemotherapy. The response rate was 70% (complete response in two; partial response in 14). Among 12 patients (67%) who underwent conversion surgery, R0 resection was conducted in eight, and no residual tumour was observed in two. For the population overall, the median overall survival was 24 months (95% confidence intervaI=21 months-not reached) and the 1-year overall survival rate was 95% (95% confidence intervaI=67-98%). Grade 3/4 neutropenia and grade 2 peripheral sensory neuropathy occurred in five (22%) and six (26%) patients, respectively, while no patient developed grade 3/4 thrombocytopenia. Conclusion: Chemotherapy with itraconazole is promising for patients with unresectable gastric cancer.
机译：目的：评价化疗与伊丙唑治疗晚期或复发性胃癌的疗效。患者及方法：人表皮生长因子受体2（HER2）所提及的医院的负不可切除的胃癌患者。方案包含160mg / m（2）Nab-Paclitaxel i.v.和100 mg / m2 oxaliplatin i.v.在第1天，在第1-3天口服60mg / m 2 S-1，并在第2天至2日口服1-2天，每2周重复6-8个循环。结果：203名患者40-80岁（中位年龄= 68岁）均被招募，其中21例胃癌和两种胃食管结癌。关于阶段，二，一和20名患者分别具有IIIA，IIIB和IV阶段。在肝脏转移患者中，2/10具有同时肺转移。九名患者患有腹膜传播，5例阶段阶段疾病患者在初级手术后发生复发，然后进行佐剂S-1。另外18名患者没有手术或化疗的历史。响应率为70％（两者完全响应; 14年部分响应）。在12名患者中（67％）接受转化手术的患者中，R0切除术在八次中进行，两者中没有观察到残留的肿瘤。对于人口总体而言，中位数全身生存率为24个月（95％的置信速度= 21个月 - 未达到），而1年的总体生存率为95％（95％置信速度= 67-98％）。 3/4级中性蛋白和2级外周血感觉神经病变分别发生在五（22％）和六（26％）患者中发生，而没有患者发育3/4血小板减少症。结论：与伊丙酮唑唑的化疗对不可切征的胃癌患者具有很大的观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号